VKTX Stock Analysis: Buy, Sell, or Hold?
VKTX - Viking Therapeutics, Inc
$32.37
1.99 (6.55%)
▲
5d:
+12.59%
30d:
+9.95%
90d:
+0.12%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jul 22, 2026
28d
Smart Money Distribution
None View Scanner →
Strength: 8.2/10
Get Alerted When VKTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VKTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VKTX is currently trading at $32.37, which is considered extended relative to its 30-day fair value range of $28.74 to $31.38.
Technical Outlook: Technically, VKTX is showing sideways momentum. The price is approaching resistance at $32.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: VKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $92.58 (+186.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VKTX is showing sideways momentum. The price is approaching resistance at $32.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.6% recently.
Market Sentiment: VKTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $92.58 (+186.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.74 -
$31.38
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.6%)
- BULLISH: Trading 186.0% below Wall St target ($92.58)
Trading Range Analysis
30-Day Trading Range
$28.74 -
$31.38
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.16
Resistance Level
$32.90
Current Trend
Sideways
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.09
Wall Street Target
$92.58
(+186.0%)
Share & Embed Analysis
Last updated: June 23, 2026 9:03 AM ET
Data refreshes hourly during market hours. Next update: 10:03 AM
Data refreshes hourly during market hours. Next update: 10:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VKTX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Neil William Aubuchon
BUY
4475 shares
2026-03-10
Brian Lian
SELL
233409 shares
2026-01-05
Greg Zante
SELL
57661 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 59 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 63 BUY |
